Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR10.40), EUR7.75 worse than the analyst estimate of (EUR2.65). Revenue for the quarter came in at EUR51.17 million versus the consensus estimate of EUR19.55 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.